Geron Corporation
GERN
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of lowā¦ read more
Healthcare
Biotechnology
29 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.33
Price-0.75%
-$0.01
1Y
Price
Market Cap
$849.013m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-20.4%
EBITDA Margin-39.0%
Net Profit Margin-28.6%
Free Cash Flow MarginRevenue
$183.403m
+138.2%
1y CAGR+10821.6%
3y CAGR+8101.9%
5y CAGREarnings
-$79.990m
+54.2%
1y CAGR+9.9%
3y CAGR+1.9%
5y CAGREPS
-$0.12
+55.6%
1y CAGR+28.2%
3y CAGR+21.2%
5y CAGRBook Value
$248.707m
$567.382m
Assets$318.675m
Liabilities$121.916m
DebtDebt to Assets
21.5%
-2.7x
Debt to EBITDAFree Cash Flow
-$132.823m
+39.4%
1y CAGR-7.5%
3y CAGR-14.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company